by Will Figueiredo | Oct 13, 2021 | News
September 29, 2021 Amring Pharmaceuticals Inc, a niche generic and brand pharmaceutical company, announced a license agreement with Pierre Fabre Farma de Mexico, S.A. de C.V. for LYSTEDA (tranexamic acid). Read more
by Will Figueiredo | Aug 9, 2021 | News
August 5, 2021 Amring Pharmaceuticals Inc., a niche brand and generic pharmaceuticals company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP and has immediately begun commercialization activity. Read...
by Will Figueiredo | Mar 15, 2021 | Uncategorized
March 12, 2021 Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program that will bring critical and accessible therapy for patients in need. Read more
by Will Figueiredo | Dec 2, 2020 | Uncategorized
December 2, 2020 Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced the acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy...
Recent Comments